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Diffuse large B cell lymphoma (DLBCL) is a complex
disease comprising diverse subtypes and genetic
profiles. Possibly because of the prevalence of ge-
netic alterations activating canonical NF-kB activity,
a role for oncogenic lesions that activate the alterna-
tive NF-kB pathway in DLBCL has remained elusive.
Here, we show that deletion/mutation of TRAF3, a
negative regulator of the alternative NF-kB pathway,
occurs in 15% of DLBCLs and that it often coex-
ists with BCL6 translocation, which prevents termi-
nal B cell differentiation. Accordingly, in a mouse
model constitutive activation of the alternative NF-
kB pathway cooperates with BCL6 deregulation in
DLBCL development. This work demonstrates a key
oncogenic role for the alternative NF-kB pathway in
DLBCL development.INTRODUCTION
Diffuse large B cell lymphoma (DLBCL), the most common form
of non-Hodgkin’s lymphoma, is a genetically, phenotypically,
and clinically heterogeneous disease. Various DLBCL subtypes
have been revealed by gene expression profile analysis using
distinct classification schemes, which is according to their puta-tive cell of origin or the coordinated expression of consensus
clusters (Alizadeh et al., 2000; Monti et al., 2005). In the ‘‘cell of
origin’’ (COO) classification, two main subtypes of DLBCL have
been identified in which transcriptional programs resemble
normal B cells at particular developmental stages. These are
the germinal center B cell (GCB)-like DLBCL, presumably
derived from a GC B cell, and the activated B cell (ABC)-like
DLBCL, in which the cell of origin is less clear but may corre-
spond to a cell undergoing plasmacytic differentiation (Lenz
and Staudt, 2010; Wright et al., 2003).
Analysis of the coding genome of DLBCL has identified
various genetic lesions and revealed their association with the
GCB or ABC subtype. Inactivating mutations and deletions of
BLIMP1/PRDM1, a key gene in terminal B cell differentiation,
are found exclusively in the ABC subtype (30% of cases) (Man-
delbaum et al., 2010; Pasqualucci et al., 2006; Tam et al., 2006).
Similarly BCL6 expression is deregulated by chromosomal
translocation more frequently in the ABC (26% of cases) than
in theGCB subtype, where BCL6 expression is high a priori (Iqbal
et al., 2007; Mandelbaum et al., 2010; Pasqualucci et al., 2011).
Interestingly, BCL6 translocations are mutually exclusive with
BLIMP1 structural alterations in ABC-DLBCL (Mandelbaum
et al., 2010). Given that BCL6 can directly suppress BLIMP1
expression (Tunyaplin et al., 2004), it has been hypothesized
that BCL6 translocations represent an alternative mechanism
for BLIMP1 inactivation in ABC-DLBCL, although BCL6 controls
multiple additional functions in GC B cells (Mandelbaum et al.,
2010). Another group of mutations promote constitutive NF-kBCell Reports 11, 715–726, May 5, 2015 ª2015 The Authors 715
Figure 1. Recurrent TRAF3 and BCL6 Le-
sions in DLBCL
(A) Diagram of the TRAF3 protein, with its rele-
vant functional domains. The mutations found in
DLBCL are indicated.
(B) Inferred log2 copy-number (CN) data from
representative DLBCL cases carrying deletions
encompassing TRAF3 compared with normal
controls. The position of TRAF3 and its neigh-
boring gene RCOR1 is indicated. In the red-blue
scale, white corresponds to a normal (diploid) CN
log ratio; blue is deletion, and red is gain. *Case
2147 harbored a point mutation in the residual
allele, leading to biallelic inactivation.
(C) Overall frequency of TRAF3 genetic lesions
(point mutations and deletions) in DLBCL pheno-
typic subtypes. Forty-seven GCB and 51 ABC/
NC-DLBCL biopsies, 14 GCB and 7 ABC-DLBCL
cell lines were included in this analysis (the primary
tumors and cell lines of each DLBCL subtype
displayed similar frequencies of TRAF3 lesions).
Note that among the 119 samples, 29 lack CN
data; thus, the frequencies shown may represent
an underestimate.
(D) Percentage of DLBCL primary cases showing
nuclear p52 staining, as a readout of noncanonical
NF-kB activation, in TRAF3M/D versus TRAF3WT
cases. The cutoff used to score cases as nuclear
positive wasR20% (Compagno et al., 2009).
(E) Relative distribution of genetic lesions affecting
TRAF3, BCL6, and PRDM1 in individual DLBCLs.
Each column represents one patient, with color codes indicating the presence or absence of the corresponding feature (Tx, translocation; M/D, mutations and/or
deletions). Only the 90 samples with full information on TRAF3 M/D, BCL6 Tx, and PRDM1 M/D are included. P^RDM1 genetic lesions only include biallelic
deletions or point mutations since the functional significance of large 6q monoallelic deletions is unclear. Details of PRDM1 and BCL6 lesions have been
described previously (Mandelbaum et al., 2010; Pasqualucci et al., 2006).
See also Figure S1.activation, such as those affecting TNFAIP3 (A20), CD79B, and
MYD88, predominantly in the ABC subtype (Compagno et al.,
2009; Davis et al., 2010; Ngo et al., 2011; Pasqualucci et al.,
2011), and CARD11 mutations occurring in both subtypes
(Lenz et al., 2008; Pasqualucci et al., 2011).
Notably, NF-kB activating mutations in DLBCLs, including the
ones described above, predominantly involve the NF-kB canon-
ical pathway (Compagno et al., 2009; Davis et al., 2010; Lenz
et al., 2008; Ngo et al., 2011; Pasqualucci et al., 2011; Staudt,
2010). As a consequence, a role for putative genetic lesions
involving the NF-kB alternative pathway remained largely over-
looked. Supporting a role of the NF-kB alternative pathway in
DLBCL pathogenesis, 10% of DLBCLs were found to stain
positive for NF-kB2 p52 but not NF-kB1 p50 in the nucleus,
and another 20% of cases exhibited both NF-kB1 and NF-kB2
nuclear staining (Compagno et al., 2009); furthermore, a recent
study revealed that roughly 10% of DLBCLs carry deletions or
mutations of TRAF3 or TRAF2 (Pasqualucci et al., 2011).
TRAF3 and TRAF2 control the degradation of NF-kB-inducing ki-
nase (NIK) and consequently restrain activation of the alternative
NF-kB pathway (Gardam et al., 2008; Ha¨cker et al., 2011; Sasaki
et al., 2008).
Although an oncogenic role for constitutive canonical NF-kB
activity has been demonstrated in a mouse model of DLBCL
(Calado et al., 2010), a functional link between the activation of716 Cell Reports 11, 715–726, May 5, 2015 ª2015 The Authorsalternative NF-kB pathway and the pathogenesis of DLBCL re-
mained to be established. In this study, we performed comple-
mentary human and mouse studies to investigate mutations
activating the alternative NF-kB pathway and concurrent genetic
events and developed a genetic system in the mouse to test the
role of constitutive alternative NF-kB signaling in the pathogen-
esis of DLBCL.
RESULTS
TRAF3Gene Lesions Coexist withBCL6 Translocation in
Human DLBCL
Deletions and mutations of TRAF3 have been found in human
DLBCLs (Pasqualucci et al., 2011). To have a deeper look into
TRAF3 genetic lesions and their distribution in DLBCL subtypes,
we analyzed the TRAF3 sequences for the presence of point mu-
tations and copy-number aberrations in 119 DLBCL samples,
including 98 biopsies and 21 cell lines whose phenotypic sub-
type was known. This analysis revealed missense, frameshift,
and nonsense mutations (the two mutations tested being both
somatic in origin) in functional domains, which are required for
TRAF3 to negatively regulate NIK protein stability (Figure 1A; An-
nunziata et al., 2007; Ha¨cker et al., 2011; He et al., 2007; Keats
et al., 2007). Specifically, we identified one DLBCL case carrying
a frameshift mutation (284 fs) and one carrying a nonsense
mutation (R310X), both of which are predicted to disrupt the
MATH domain, required for the interaction between TRAF3
and NIK (Ha¨cker et al., 2011; He et al., 2007). One additional
DLBCL harbored a missense mutation (H70R) that may alter
the function of the RING domain, required for the negative regu-
lation of NIK by TRAF3 (He et al., 2007). Notably, a missense mu-
tation affecting the H70 residue has been previously reported in a
multiple myeloma patient (Keats et al., 2007). The present anal-
ysis also identified biallelic or monoallelic deletions involving
the TRAF3 locus, including two focal homozygous losses that
encompass TRAF3 and its neighboring geneRCOR1 (Figure 1B).
A similar spectrum of deletions has been observed in human
multiple myeloma and was shown to stabilize the NIK protein
(Annunziata et al., 2007; Keats et al., 2007). TRAF3 deletions/mu-
tations occurred similarly in GCB and ABC DLBCL (Figure 1C)
and significantly correlated with alternative NF-kB activation,
indicated by nuclear p52 staining (Figure 1D).
We previously observed that constitutive canonical NF-kB
activation promotes DLBCL development upon disruption of ter-
minal B cell differentiation via inactivating BLIMP1 (Calado et al.,
2010). With these observations in mind, we searched whether
TRAF3 mutations in DLBCL associate with BCL6 or BLIMP1 ge-
netic lesions, either of which would presumably disrupt terminal
B cell differentiation (Mandelbaum et al., 2010). While none of the
17 DLBCLs carrying TRAF3 deletions/mutations exhibited bial-
lelic BLIMP1 deletion/mutation, 6 of them (35%) had concurrent
BCL6 translocation (the small number of cases analyzed did not
provide statistical power to assess whether the co-occurrence is
significant) (Figures 1E and S1).
Taken together, these data show that roughly 15% of DLBCLs
carry TRAF3 genetic alterations and that these lesions often
coexist with BCL6 translocations.
Impact of Alternative NF-kB Activation and/or BCL6
Deregulation on the GC Reaction
To study the impact of enforced alternative NF-kB activation and
BCL6 deregulation on the pathogenesis of DLBCL, we used a
system of conditional gain- and/or loss-of-function mutagenesis
in mice. Given that DLBCL arises from a GC or post-GC B cell
(Shaffer et al., 2012), we decided to perform targeted mutagen-
esis in GC B cells, using the Cg1-cre transgene, from which Cre
is expressed in B cells at an early stage of the GC reaction (Ca-
sola et al., 2006). To induce activation of the alternative NF-kB
pathway, we combined this transgene with a ROSA26 allele
harboring a cDNA encoding NIK, preceded by a loxP flanked
STOP cassette (hereafter called NikstopFL) (Sasaki et al., 2008).
NIK expression from the mutant ROSA26 allele is indicated by
a GFP reporter controlled by an internal ribosome entry site
(Sasaki et al., 2008). For BCL6 deregulated expression, we
used an HA-tagged BCL6 transgene inserted into the immuno-
globulin (Ig) heavy-chain locus downstream of Im promoter
(hereafter called ImBcl6), mimicking the observed BCL6/IgH
translocation in DLBCL (Cattoretti et al., 2005). To monitor Cre-
mediated recombination in cells of compound mutant mice
not carrying the NikstopFL allele, we used a conditional YFP re-
porter allele in the ROSA26 locus designated YFPstopFL (Srinivas
et al., 2001). Mice carrying the Cg1-cre and YFPstopFL alleles
served as controls.To test the impact of alternative NF-kB pathway activation,
alone or together with enforced BCL6 expression, on GC B
cell formation, we immunized experimental and control mice
with sheep red blood cells (SRBCs). Analysis 10 days after im-
munization revealed expression of the reporter, GFP or YFP, in
the majority of GC B cells, indicating efficient Cre-mediated
recombination in mice of all genotypes analyzed (Figure 2A).
Control mice and mice with enforced expression of NIK and/
or BCL6 also showed similar fractions of GC B cells at day 10
after primary immunization (Figures 2A and 2C). However, at
day 21 postimmunization, mice with enforced NIK expression
and thus constitutive alternative NF-kB activation alone had a
significantly reduced fraction of GC B cells compared with con-
trol mice (Figures 2B and 2C), similar to what is seen inmicewith
constitutive canonical NF-kB activation in GC B cells (Calado
et al., 2010). Enforced NIK expression in GC B cells led to
increased expression of IRF4, which might, in turn, account
for upregulation of BLIMP1 and downregulation of BCL6 in
these cells (Figure 2D; Saito et al., 2007; Sciammas et al.,
2006). We considered the possibility that the premature termi-
nation of the GC reaction in mice with enforced NIK expression
might be due to the altered expression of BLIMP1 or BCL6 (Cal-
ado et al., 2010; Martins and Calame, 2008; Ye et al., 1997);
however, concomitant BLIMP1 deletion (data not shown) or
BCL6 enforced expression did not prevent GC early termination
in thesemice (Figures 2B and 2C). We next looked whether acti-
vation of the alternative NF-kB pathway alone or together with
enforced BCL6 expression affects physiological processes of
GC B cells, such as somatic hypermutation. At day 21 postim-
munization, GC B cells from mice with enforced NIK or BCL6
expression alone carried slightly reduced numbers of somatic
mutations in their Ig heavy-chain (IgH) V regions, compared
with controls, while those from mice with enforced expression
of both NIK and BCL6 had significantly fewer mutations (Fig-
ure 2E). The reduced somatic mutation load in the latter group
is likely due to premature termination of the GC reaction, as
similar levels of somatic mutation and AICDA expression were
detected in GC B cells from these mice and controls when
analyzed at day 10 after immunization, the peak time of the
GC reaction (Figures 2C, 2E, and 2F). Collectively, these results
demonstrate that constitutive activation of NF-kB signaling
through enforced NIK expression negatively impacts the GC re-
action and that this effect is independent of BCL6 regulation.
Hence, constitutive NF-kB activation is incompatible with the
maintenance of a GC B cell phenotype and may in a similar
way impact the phenotype of lymphoma cells arising in the
context of the GC reaction (see Discussion).
Enforced Activity of the Alternative NF-kB Pathway
Enhances B Cell Proliferation and Survival
To evaluate the impact of the constitutive expression of NIK and/
or BCL6 on B cell proliferation and survival, we used an
in vitro cell culture system where Cre-mediated recombination
is induced in B cells upon treatment with anti-CD40 and inter-
leukin 4 (IL-4), mimicking T cell-dependent B cell activation
(Calado et al., 2010). NF-kB activation through enforced expres-
sion of NIK not only improved survival of ABCs but also
increased their proliferation (Figures 3A–3C). Interestingly, inCell Reports 11, 715–726, May 5, 2015 ª2015 The Authors 717
Figure 2. Impact of Constitutive NIK and BCL6 Expression on the GC Reaction
(A and B) Representative FACS analysis of splenic GC B cells at day 10 (A) and day 21 (B) after primary immunization with SRBCs, respectively. (Upper) The GC B
cell population (within the gate; CD19+FashiCD38lo). (Lower) Reporter expression in GC B cells.
(C) Summary of FACS analysis of GC B cells as in (A) and (B). Black bar represents mean for each genotype of mice at the indicated time points.
(D) Real-time PCR analysis of the expression levels of the indicated genes in reporter-positive GCB cells at day 10 after primary immunization with SRBCs. Values
represent normalized levels to HPRT. Data are represented as mean ± SEM.
(E) IgH somatic mutation in reporter-positive GC B cells at day 10 (13 to 16 sequences per mouse from two to three mice per genotype) and day 21 (12–16
sequences per mouse from two to three mice per genotype) after primary immunization with SRBCs. Black bar represents mean. Average mutation frequency at
day 21 is shown in graph.
(F) Real-time PCR analysis of AICDA transcript levels in reporter-positive GC B cells at day 10 after primary immunization with SRBCs. Values represent
normalized levels to HPRT. Data are represented as mean ± SEM.
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Figure 3. Enhanced Cellular Proliferation
and Survival as a Result of Constitutive
NIK Expression
(A) Cre-mediated recombination efficiency in pu-
rified B cells frommice of the indicated genotypes,
cultured in vitro in the presence of anti-CD40 plus
IL-4, measured by expression of reporter genes at
days 2 and 5 of the culture.
(B) Proliferation of in vitro cultured B cells treated
as in (A), measured by CellTrace dilution of re-
porter-positive cells at day 5 of the culture. The
numbers under CellTrace peaks indicate the
number of cell divisions.
(C) Frequency of apoptotic cells, at day 5, within
in vitro cultured B cells treated as in (A), measured
by active Caspase3 staining.
(D) Relative number of live cells at the indicated
time points in in vitro culture of splenic B cells
treated as in (A), normalized to day 2.
Data in (A–D) are representative of two indepen-
dent experiments performed in triplicate; data in
(C) are shown asmean ± SEM of triplicates; data in
(D) are shown as mean ± SD of triplicates.this experimental system, concurrent BCL6 expression did not
further enhance these effects (Figures 3A–3C). Overall, constitu-
tive NIK expression led to the accumulation of increased
numbers of cells in culture, with concomitant BCL6 expression
having no additional effect (Figure 3D).
BCL6 Enforced Expression through a BCL6/IgH
Translocation Blocks Plasma Cell Differentiation
Induced by Constitutive Alternative NF-kB Signaling
Enforced expression of NIK in GC B cells promoted transcription
of IRF4 (Figure 2D), a key transcription factor for plasma cell dif-
ferentiation (Klein et al., 2006). Accordingly, SRBC-immunized
Cg1-cre/+;NikstopFL mice displayed a significantly enlarged
plasma cell compartment after primary and secondary immuni-
zation compared with controls (Figures 4A, 4B, and S2A). In
accord with the notion that BCL6 represses BLIMP1 transcrip-
tion (Figure 2D; Tunyaplin et al., 2004) and the latter is essentialCell Reports 11, 715for plasma cell differentiation (Martins
and Calame, 2008), the plasma cell
compartment was significantly reduced
in Cg1-cre/ImBcl6;NikstopFL mice com-
pared with Cg1-cre/+;NikstopFL mice (Fig-
ures 4A, 4B, and S2A). In line with the
in vitro data that enforced alternative
NF-kB activity enhances B cell pro-
liferation and survival, while concurrent
BCL6 expression has no additive
effect (Figure 3), Cg1-cre/+;NikstopFL
mice displayed increased numbers of
total reporter positive cells (containing
both plasma cells and B cells) in
spleen compared to controls (Cg1-cre/+;
YFPstopFL), and these numbers were
not further increased in mice with
concurrently enforced expression ofBCL6 (Cg1-cre/ImBcl6;NikstopFL mice) (Figures 4A and S2B).
Collectively, these data suggest that a major effect of the de-
regulated BCL6 expression in GC B cells is a block of plasma
cell differentiation.
Mice with Enforced NIK and BCL6 Expression in GC B
Cells Display a Shortened Lifespan
Next, we assessed the role of alternative NF-kBactivationwith or
without concomitant BCL6 deregulation in B cell malignant
transformation by monitoring the mice for tumor development
over a period of 1.5 years (78weeks). Micewith enforced expres-
sion of NIK displayed a similar lifespan as controls, while 40%
of Cg1-cre/ImBcl6 mice died prematurely (Figure 5), consistent
with a previous report (Cattoretti et al., 2005). In contrast, all
mice with concurrent NIK and BCL6 enforced expression died
within the observation period, suggesting a cooperative role
(Figure 5).–726, May 5, 2015 ª2015 The Authors 719
Figure 4. Plasma Cell Differentiation
Induced by NIK Expression Is Largely Abol-
ished upon Coexpression of BCL6
(A) Representative FACS analysis of plasma cells
in spleen at day 14 after secondary immunization.
Reporter-positive splenic cells from mice of the
indicated genotypes were gated (upper) for the
analysis of plasma cells (B220loCD138+; lower).
(B) Summary of FACS analysis of plasma cells in
spleen at day 10 after primary immunization and
day 14 after secondary immunization. Black bar
represents mean.
See also Figure S2.Plasma Cell Hyperplasia in Mice with Constitutive
Alternative NF-kB Signaling
We decided to analyze the Cg1-cre/+;NikstopFL mice in more
detail and sacrificed them at the end of the observation period
(1.5 years). Mice with enforced NIK expression displayed
enlarged spleens (Figure 6A) and had a significant hyperplasia
of both B cells and plasmablasts/plasma cells in spleen and
bone marrow compared with age-matched control animals (Fig-
ures 6B and S3). Histological analysis revealed dramatically
increased numbers of spleen cells expressing the plasma cell
marker CD138 and intracellular Ig (Figure 6C). Serum protein
electrophoresis further revealed that 8/9 of Cg1-cre/+;NikstopFL
mice displayed a distinct band in the g-globulin region of the720 Cell Reports 11, 715–726, May 5, 2015 ª2015 The Authorsgel (M-spike), in contrast to three of
nine of controls (Figure 6D; data not
shown), indicative of clonal plasma cell
expansion. We conclude that enforced
activation of alternative NF-kB signaling
promotes B cell hyperplasia, in accord
with previous work (Sasaki et al., 2008),
as well as an expansion of the plasma
cell compartments in spleen and bone
marrow.
Alternative NF-kB Signaling
Cooperates with Deregulated BCL6
in DLBCL Pathogenesis
Macroscopic examination of terminally ill
Cg1-cre/ImBcl6 (6 cases) and Cg1-cre/Im
Bcl6;NikstopFL (10 cases) mice revealed
splenomegaly and lymphadenopathy in
all cases (Figure 7A). Histological exami-
nation of the enlarged lymphoid organs
showed that five of the six Cg1-cre/
ImBcl6 mice analyzed had a DLBCL-like
disease, characterized by a diffuse
growth pattern of large cells, while the re-
maining mouse had a tumor with a plas-
macytic morphology. Diseased Cg1-cre/
ImBcl6;NikstopFL mice on the other hand
all showed histological features of
DLBCL (Figure 7B; Table S1; data not
shown). By flow cytometry, these tumors
were all negative for the plasma cellmarker CD138 and displayed a mature B cell phenotype
(CD19+AA4.1IgM+ or occasionally IgG+; Table S2). Analysis
of IgH gene rearrangements by Southern blot revealed that
the DLBCLs were of clonal B cell origin and that the same tumor
clone was present in both spleen and mesenteric lymph
nodes of each mouse examined (Figure 7C), indicative of an
aggressive phenotype. We next amplified the rearranged IgH
V regions from clonal B cell tumors of Cg1-cre/ImBcl6 and
Cg1-cre/ImBcl6;NikstopFL mice (four cases each). Sequence
analysis revealed somatically mutated Ig genes in three of the
four Cg1-cre/ImBcl6 tumors and two of the four Cg1-cre/Im
Bcl6;NikstopFL tumors (Table S3), suggesting that a fraction of
the tumors derived from GC or post-GC B cells.
Figure 5. Mice with Enforced NIK and BCL6 Expression Display a
Shortened Lifespan
Kaplan-Meier survival curves of mice of the indicated genotypes.The activation of the alternative NF-kB pathway was
confirmed in all tumors from Cg1-cre/ImBcl6;NikstopFL mice by
the enhanced processing of p100 to p52 on the immunoblot
compared with tumors from Cg1-cre/ImBcl6 mice (Figure 7D).
In an attempt to subclassify the lymphomas occurring in our
mouse cohorts according to the COO classification scheme,
we performed immunohistochemistry (IHC) and gene expression
profiling (GEP) by RNA sequencing (RNA-seq). By IHC, expres-
sion of IRF4/MUM1 usually segregates with ABC-DLBCL, while
high levels of BCL6 expression often associate with GCB-
DLBCL (Choi et al., 2009; Hans et al., 2004), although a fraction
of ABC-DLBCLs also expresses BCL6 in part due to BCL6 trans-
location to the IgH locus (Iqbal et al., 2007; Lenz and Staudt,
2010). All tumors analyzed were BCL6 positive, in line with the
presence of the ImBcl6 allele mimicking the BCL6/IgH chromo-
somal translocation (Figure 7E; Table S1). However, the expres-
sion was varied and particularly low in the cases where NIK
expression was enforced (Figures 7D and 7E; Table S1). These
observations suggest that the alternative NF-kB pathway was
able to inhibit BCL6 expression from its endogenous loci, but
not from the transgene, similar to what had been observed for
the canonical pathway (Figure 2D; Cattoretti et al., 2005; Saito
et al., 2007). IHC for IRF4, on the other hand, revealed that all
lymphomas (five of five) arising in Cg1-cre/ImBcl6;NikstopFL
mice were IRF4hi, while a more varied pattern was observed in
tumors arising in Cg1-cre/ImBcl6 mice, with two IRF4hi tumors,
one tumor displaying both IRF4dim and IRF4hi cells and one IR-
F4lo/neg tumor (Figure 7E; Table S1). To subclassify these
DLBCLs, we compared their GEP to that of GC B cells and
in vitro ABCs, in analogy to the strategy used for classification
of human DLBCLs (Alizadeh et al., 2000). This analysis revealed
that three (#603, #604, #775) of five DLBCLs arising in Cg1-cre/
ImBcl6 mice displayed a GEP similar to GC B cells, indicative of
the GCB subtype, while the GEP of the remaining two (#607,
#1128) Cg1-cre/ImBcl6 lymphomas resembled that of ABCs. Of
note, tumors #607 and #1,128 were also IRF4hi by IHC, further
supporting an ABC subtype classification. In contrast, mostDLBCLs (six of seven; #817, #773, #920, #776, #611, #1,078)
occurring upon activation of the alternative NF-kB pathway
together with enforced BCL6 expression (Cg1-cre/ImBcl6;
NikstopFL mice) displayed a GEP similar to that of ABCs (Fig-
ure 7F). The remaining Cg1-cre/ImBcl6;NikstopFL DLBCL (#818)
had a GEP resembling that of GC B cells, but because it stained
highly positive for IRF4, we considered it ‘‘nonclassified.’’ Thus,
in our experimental system, the alternative NF-kB pathway and
BCL6 synergize in the development of lymphomas that, in
most cases, resemble ABC-DLBCL.
Mutations in Genes of the Canonical NF-kB Pathway in a
Fraction of Mouse DLBCLs
Our genetic analysis revealed that a fraction (6 of 17) of human
DLBCLs carrying a mutated TRAF3 gene have an additional
mutation(s) in genes of the canonical NF-kB pathway (Fig-
ure S1). In the tumors of Cg1-cre/ImBcl6;NikstopFL mice we de-
tected variable levels of phospho-IkBa at Ser32/26 (Figure 7D).
Phosphorylation at these residues indicates canonical NF-kB
activation (Brown et al., 1995; Traenckner et al., 1995). For
that reason we decided to analyze the RNA-seq data of the
DLBCLs arising in the compound mutant mice for acquired
mutations affecting genes within the canonical NF-kB pathway
(for the list of genes, see Supplemental Experimental Proce-
dures). Interestingly, we found such mutations in two of seven
DLBCLs arising in Cg1-cre/ImBcl6;NikstopFL mice (Figure S4).
More specifically, DLBCLs #773 and #776 harbored the
same mutation (R218H) in the MYD88 gene, and increased
levels of phospho-IkBa were seen in DLBCL #773 compared
with other tumors of the same genotype and normal splenic
tissue from a Cg1-cre/+ mouse (Figure 7D), suggesting a func-
tional role for this mutation (Ngo et al., 2011). We also analyzed
RNA-seq data of the DLBCLs arising in mice with enforced
BCL6 expression alone for the presence of mutations in genes
of both canonical and alternative pathways of NF-kB (for the
list of genes, see the Supplemental Experimental Procedures).
We found that two of five such DLBCLs had acquired muta-
tions in either the CK1a kinase or CARD11 gene (Figure S4; Bi-
de`re et al., 2009; Lenz et al., 2008). DLBCL #1,128 had a
mutation in the CK1a kinase domain and displayed elevated
phospho-IkBa compared with the normal spleen control (Fig-
ure 7D). These observations are consistent with the observed
IRF4 expression in this tumor and classification as ABC-
DLBCL (Figure 7F). Another Cg1-cre/ImBcl6 derived DLBCL
(#603) displayed a mutation in the CARD11 (D401N) coiled-
coil domain, to which the CARD11 mutations in human DLBCL
are confined (Lenz et al., 2008), and this lymphoma also
showed elevated levels of phospho-IkBa compared with the
normal spleen control (Figure 7D). Despite canonical NF-kB
pathway activation, this tumor was classified as a GCB-
DLBCL by GEP profiling. Interestingly, the same exact muta-
tion has been found in a human GCB-DLBCL (Morin et al.,
2011). This is consistent with previous observations in human
DLBCL, where canonical NF-kB activation could be detected
in 20% of GCB-DLBCLs (Compagno et al., 2009). Collec-
tively, our data show that a fraction of the tumors arising in
both Cg1-cre/ImBcl6 and Cg1-cre/ImBcl6;NikstopFL mice has
acquired mutations in genes of the canonical NF-kB pathwayCell Reports 11, 715–726, May 5, 2015 ª2015 The Authors 721
Figure 6. Plasma Cell Hyperplasia in Mice
with Constitutive Alternative NF-kB Sig-
naling
(A) Representative picture of spleens from aged
mice (R60 weeks) of the indicated genotypes.
Three or more mice per genotype were analyzed.
(B) Number of reporter-positive plasma cells
(B220loCD138+) in spleen and bone marrow of
aged mice of the indicated genotypes. Black bar
represents median. The statistics was analyzed
using unpaired, nonparametricMann-Whitney test
(comparing ranks).
(C) Representative histological (H&E) and immu-
nohistochemical (CD138 and Ig) staining of
spleens from aged mice of the indicated geno-
types. Three or more mice per genotype were
analyzed. Scale bar represents 1,000 mm; inset
represents 200 mm.
(D) Serum protein electrophoresis of representa-
tive samples from aged mice of the indicated ge-
notypes. The position of albumin and of various
globulin components of the serum is indicated.
Red arrowhead indicates M spike. In total, three of
nine (33%) of Cg1-cre/+;YFPstopFL mice and eight
of nine (89%) of Cg1-cre/+;NikstopFL mice display
M spike, respectively.
See also Figure S3.that are also affected in human DLBCL (Compagno et al.,
2009; Pasqualucci et al., 2011).
DISCUSSION
A Causal Role of Alternative NF-kB Activation in DLBCL
Recent studies of humanDLBCLs have identified various genetic
lesions that activate NF-kB through the canonical pathway and
revealed their association predominantly with the ABC over the
GCB subtype (Compagno et al., 2009; Davis et al., 2010; Kato
et al., 2009; Lenz et al., 2008; Ngo et al., 2011; Pasqualucci
et al., 2011), in accord with the observation that ABC-DLBCL
but not GCB-DLBCL cell lines rely on constitutive canonical
NF-kB signaling for survival (Davis et al., 2001; Staudt, 2010). Us-
ing a mousemodel, we had previously established an oncogenic
role for constitutive canonical NF-kB activity in ABC-DLBCL
pathogenesis (Calado et al., 2010). In contrast, the question of
whether enforced activation of the alternative NF-kB pathway
can be functionally involved in DLBCL pathogenesis has not
been addressed, despite several observations suggesting a
role for this pathway in the disease. Thus, mutations affecting
genes (TRAF3 and TRAF2) of the alternative NF-kB pathway
have been observed in a subset of human DLBCLs (Pasqualucci
et al., 2011); the NF-kB2 gene, encoding the core molecule for
this signaling pathway, was originally identified by virtue of its
translocation to the IgH locus in a case of DLBCL (Neri et al.,
1991), and IHC data revealed nuclear NF-kB2 p52, reflecting
activation of the alternative pathway, in a subset of both GCB722 Cell Reports 11, 715–726, May 5, 2015 ª2015 The Authorsand ABC-DLBCL (Compagno et al.,
2009). While these data demonstrated
alternative NF-kB activity in a subset of
DLBCLs, a paper by Pham et al. (2011)claimed that in DLBCLs of all subtypes both the canonical and
alternative NF-kB pathways are activated through constitutive
BAFF-R (BR3) signaling. However, in most DLBCL cell lines
analyzed, there was no evidence for robust degradation of
p100 to p52.
To clarify these matters and in particular to obtain functional
evidence for a contribution of alternative NF-kB signaling
to DLBCL pathogenesis, we first extended the analysis of
TRAF3 mutations by studying a larger number of DLBCL
primary tumors and examining the association of TRAF3 muta-
tions with the ABC or GCB subtype. These analyses demon-
strated that biallelic or monoallelic deletions/mutations of
TRAF3 occur recurrently in similar fractions (15%) of ABC-
DLBCL and GCB-DLBCL and correlate with alternative NF-
kB activity in these cases. We then developed a mouse model
system that allows conditional activation of the alternative NF-
kB pathway in a GC B-cell-restricted manner and found that
activation of this pathway, in concert with BCL6 deregulation,
leads to the development of DLBCL. This indicates a causal
role of deregulated alternative NF-kB signaling in DLBCL path-
ogenesis. Interestingly, in this scenario, the deregulation of
alternative NF-kB activity appears to be required in the
context of GC B cell differentiation. Deletion of TRAF3 in
mouse B cells from early developmental stages via CD19-
cre leads to the formation of B1 and marginal zone B cell
lymphomas, not DLBCL (Moore et al., 2012). These tumors
resemble human splenic marginal zone lymphoma (SMZL),
where inactivating mutations of TRAF3 have also been found
Figure 7. Constitutive Alternative NF-kB
Activation Synergizes with BCL6 in DLBCL
Formation and Progression
(A) Representative pictures of spleens and
mesenteric lymph nodes from mice of the indi-
cated genotypes.
(B) Representative H&E staining of spleens from
compound mutant and control mice. Scale bar
represents 1,000 mm; inset represents 200 mm.
See a summary of histological findings in Table S1.
(C) Southern blot analysis of tumor clonality using
a JH4 probe. Dashed line represents germline
IgH configuration. Spl, spleen; mLN, mesenteric
lymph node. Clonal tumors usually exhibit two
nongermline bands corresponding to VDJ and DJ
rearrangements in IgH alleles.
(D) Immunoblot analysis of various proteins in tu-
mor tissues from the indicated compound mutant
mice or in normal spleen from aCg1-cre/+mouse.
Tumor tissues, spleens of tumor-bearing mice
(only those containing50% of lymphoma B cells,
as determined by FACS analysis, were selected
for this assay). b-actin serves as loading control.
(E) Representative IHC staining for IRF4/MUM1
and BCL6 on spleen sections of lymphoma-
bearing compound mutants and an SRBC-immu-
nized control mouse. Scale bar represents
1,000 mm; inset represents 200 mm. Note that
BCL6 expression from the transgene is lower than
that from the endogenous loci of normal GCB cells
(Cattoretti et al., 2005); two Cg1-cre/ImBcl6 tu-
mors are shown, and tumor #604 shows at least
two populations, one of which shows relatively low
IRF4 staining and high BCL6 (IRF4dimBCL6hi),
while the other exhibits higher IRF4 and lower
BCL6 staining (IRF4hiBCL6dim). See the summary
of IHC results in Table S1.
(F) Comparison of gene expression profiles of the
indicated mouse tumors to that of GC B cells
(GCB), resting B cells (Resting B), or ABCs. The
protein levels of IRF4 detected by IHC staining are
noted next to the corresponding tumors (see also
E and Table S1), which complement GEP in clas-
sification of DLBCL subtypes.
See also Figure S4 and Tables S1–S3.(Rossi et al., 2011). Together, these observations highlight
the importance of ontogenetic timing in the acquisition of
oncogenic somatic mutations driving different classes of lym-
phomas. TRAF3 mutations/deletions are absent in follicular
lymphoma, Burkitt lymphoma, and B cell chronic lymphocytic
leukemia (data not shown).
Of note, we observed that mostCg1-cre/ImBcl6;NikstopFLmice
developed DLBCLs of the ABC subtype. This observation is
likely related to the fact that activation of the alternative NF-kB
pathway interferes with the GC reaction even when BCL6
expression is deregulated and suggests that, in NF-kB positive
human GCB-DLBCLs, additional mutation(s) allowing mainte-
nance of the GCB phenotype must exist. Future studies
comparing genetic lesions in the GCB versus ABC types of
DLBCLs carrying TRAF3 lesions may lead to the identification
of those latter events.Interference with Terminal B Cell Differentiation Is
Required for the Pathogenesis of ABC-DLBCL: A Role
for BCL6
Constitutive NF-kB signaling in B cells promotes their differenti-
ation toward plasma cells through induction of IRF4 (Grumont
and Gerondakis, 2000; Klein et al., 2006; Saito et al., 2007;
Sciammas et al., 2006), in line with the presence of genetic
lesions leading to constitutive NF-kB signaling in multiple
myeloma (Annunziata et al., 2007; Keats et al., 2007). The obser-
vations that ABC-DLBCLs express some key genes character-
istic of a plasmablast (Lenz and Staudt, 2010; Wright et al.,
2003), but often carry genetic lesions interfering with plasma
cell differentiation, suggest that the transformation of an ABC
into DLBCL requires interference with terminal B cell differentia-
tion (Lenz and Staudt, 2010; Staudt, 2010). Indeed, mice with
specific activation of the canonical NF-kB signaling pathway inCell Reports 11, 715–726, May 5, 2015 ª2015 The Authors 723
GCB cells developed plasma cell hyperplasia and had an overall
normal lifespan, but succumbed to ABC-like DLBCL when B-
cell-terminal differentiation was abolished by deletion of Blimp1
(Calado et al., 2010). Similarly, we show here that mice with acti-
vation of the alternative NF-kB pathway alone in GC B cells do
not succumb to tumors in the timeframe of this study but display
overt plasma cell hyperplasia and that the oncogenic role of the
alternative NF-kB pathway is revealed upon interference with
plasma cell differentiation through enforced BCL6 expression,
in accord with the coexistence of TRAF3 and BCL6 mutations
in human DLBCL.
Our work indicates that the role of BCL6 in the development
of DLBCLs exhibiting constitutive NF-kB signaling is at least in
part due to its ability to inhibit BLIMP1 expression, which in
turn limits the terminal differentiation of B cells. This is sup-
ported by data showing that in the mouse loss of BLIMP1 co-
operates with alternative NF-kB signaling in DLBCL formation
(data not shown). However, the fact that human DLBCLs with
alternative NF-kB activation are often concurrent with BCL6
translocation but not BLIMP1 inactivation suggests that other
functions of BCL6, such as repression of the DNA damage
response (Basso and Dalla-Favera, 2010), may also be criti-
cally required to complement alternative NF-kB signaling in
DLBCL development.
Alternative and Canonical NF-kB Pathway Activation in
DLBCLs
While mechanisms of aberrant NF-kB activation in DLBCL can in
the major fraction of the cases be attributed to the presence of
oncogenic mutations in genes related to the canonical NF-kB
pathway (Compagno et al., 2009; Davis et al., 2010; Lenz et al.,
2008; Ngo et al., 2011; Pasqualucci et al., 2011), previous data
and the present work show that genetic lesions activating the
alternative NF-kB pathway occur in up to 15% of DLBCLs. It is
worth noting in this context that besides the10%DLBCL cases
demonstrating nuclear NF-kB activity exclusively for the alterna-
tive pathway (indicated by nuclear staining of p52 but not p50)
20% of DLBCLs display nuclear staining for both p50 and
p52 (Compagno et al., 2009), suggesting the activation of both
canonical and alternative NF-kB pathways. Indeed, our genetic
analysis showed that a fraction (6 of 17) of TRAF3-mutated
DLBCLs carries concurrent mutation(s) in genes of the canonical
NF-kB pathway. Likewise, while the present mouse model sug-
gests that the alternative pathway can by itself drive DLBCL
development if combined with a lesion preventing plasma cell
differentiation, it became apparent that in a small fraction (two
of seven) of the resulting tumors additional mutations accumu-
lated, which resulted in the activation of canonical NF-kB
signaling. We have previously observed redundancy between
the canonical and alternative NF-kB pathways to replace
BAFF-mediated survival signals in B cells (Sasaki et al., 2006,
2008), and there is evidence in the human that NIK activation
can also trigger canonical NF-kB activity (Annunziata et al.,
2007; O’Mahony et al., 2000). Given that the NIK allele used in
the present study yields only a moderate cell survival advantage,
in sharp contrast to a NIK allele lacking the TRAF3 binding site
(Sasaki et al., 2008), we speculate that in a NIK-expressing B
cell acquisition of an activating canonical NF-kB mutation may724 Cell Reports 11, 715–726, May 5, 2015 ª2015 The Authorsconfer a further survival advantage, enabling the cell to outcom-
pete its siblings during the clonal evolution of lymphoma. A
similar mechanismmay operate in human DLBCL pathogenesis.
Overall, the current work provides a rationale for the design of
therapies targeting the alternative NF-kB pathway in a fraction
of DLBCL patients and suggests that for those human DLBCLs
that display both canonical and alternative NF-kB mutations
(Compagno et al., 2009; Pasqualucci et al., 2011), targeting
both arms of NF-kB signaling may be required for therapeutic
intervention, as recently demonstrated for multiple myeloma
(Fabre et al., 2012).
EXPERIMENTAL PROCEDURES
Sequencing Analysis and High-Density SNPArray Analysis of Human
DLBCLs
One hundred nineteen DLBCL samples, including 98 biopsies (47 GCB and
51 ABC/NC-DLBCLs) and 21 cell lines (14 GCB and 7 ABC-DLBCLs), were
analyzed as described previously (Pasqualucci et al., 2011). Oligonucleo-
tides and conditions used for TRAF3 amplification are available upon
request.
Mice, Immunization, and Tumor Cohorts
Cg1-cre, NikstopFL, Blimp1FF, ImBcl6, and YFPstopFL alleles have been
described (Casola et al., 2006; Cattoretti et al., 2005; Ohinata et al., 2005; Sa-
saki et al., 2008; Srinivas et al., 2001); 8- to 10-week-old mice were immunized
intravenously with 1 3 109 SRBCs (Cedarlane) in PBS. Mouse cohorts for tu-
mor development were given monthly antigenic stimulation by SRBC immuni-
zation for seven additional times and then monitored twice a week for tumor
development and euthanized if signs of tumor development occurred. All an-
imal care and procedures followed NIH guidelines and were approved by
the Institutional Animal Care and Use Committee (IACUC 03341) of Harvard
University and the Immune Disease Institute.
Statistical Analysis
Unless otherwise indicated, data were analyzed using unpaired two-tailed
Student’s t test; a p value% 0.05 was considered significant. A single asterisk
(*) in the graphs of figures represents p% 0.05. Double asterisks (**) represent
p% 0.01, and triple asterisks (***) represent p% 0.001; ‘‘ns’’ stands for not sta-
tistically significant, i.e., p > 0.05. Survival curves were compared using the log
rank test. Data in text and figures are represented as mean ± SEM unless
otherwise indicated.
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Figure S1. Relationship between TRAF3 Genetic Lesions and Other Recurrent 
Alterations in DLBCL, Related to Figure 1 
Relative distribution of recurrent genetic lesions in DLBCL cell lines and patient 
biopsies; Columns represent individual samples and rows correspond to distinct genetic 
lesions, grouped into separate functional categories (M, mutation, D, deletion, Tx, 
translocation, Amp, high copy number amplification; DD, DNA damage response). Red 
and white colors denote the presence or absence of the lesion, respectively; light red in 
REL indicates low copy number gains; light blue in TP53 identifies monoallelic 
deletions, the pathogenic significance of which is unclear. *, for these genes only 
biallelic alterations are shown. 
 
 3 
 
 4 
Figure S2. Constitutive BCL6 Expression Represses NIK-induced Plasma Cell 
Differentiation, Related to Figure 4 
(A) Summary of FACS analysis of reporter positive plasma cells in bone marrow (BM) at 
day 10 after primary immunization and day 14 after secondary immunization. Black bar 
represents mean. 
(B) Summary of FACS analysis of reporter positive cells in spleen of the indicated mice 
at day 14 after secondary immunization. Black bar represents mean. 
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Figure S3. Constitutive Alternative NF-κB Signaling Promotes B Cell Hyperplasia, 
Related to Figure 6 
Summary of FACS analysis of reporter positive, CD19+ B cells in spleen and bone 
marrow of aged (≥ 60 weeks) mice of the indicated genotypes. Black bar represents 
median. The statistics was analyzed using unpaired, nonparametric Mann-Whitney test. 
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Figure S4. RNA Sequencing in the Mouse Tumors Identifies Somatic Mutation of 
Genes Involved in Canonical NF-κB Signaling, Related to Figure 7 
(A) Non-silent Mutations identified by RNA sequencing in the indicated tumors, which 
were subsequently confirmed by Sanger sequencing.  
(B-D) Confirmation of somatic origin of the mutations by analysis of paired normal (tail) 
DNA. Sanger sequencing of the indicated genomic regions of CARD11 (B), CK1a (C) 
and MYD88 (D) in mouse tumors and the corresponding tails was aligned to the coding 
sequence (cDNA) of each gene. The nucleotide changes and the predicted amino acid 
changes (in parentheses) are given at the top of each figure. Shown at the bottom of 
each figure is the alignment of the indicated protein sequence in the human and mouse, 
with the mutation position denoted by a red rectangle.  7 
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Table S1. Histology and Immunohistochemistry of the Tumors, Related to Figure 7 
 
 
¶This tumor contains at least two populations, one of which is IRF4dimBCL6hi while the other is 
IRF4hiBCL6dim. See also Figure 7. Hi, high; lo/neg, low/negative. 
 
IHC Genotype Mice Organ Histology 
IRF4 BCL6 
Spleen DLBCL   611 
mLN DLBCL   
Spleen DLBCL   773 
mLN DLBCL   
Spleen DLBCL hi dim 
mLN DLBCL   
776 
tLN DLBCL   
Spleen DLBCL   
mLN DLBCL   
817 
tLN DLBCL   
Spleen DLBCL hi dim 818 
mLN DLBCL   
Spleen DLBCL hi dim 920 
mLN DLBCL   
Spleen DLBCL hi dim 1078 
mLN DLBCL   
Spleen DLBCL hi dim 
Cγ1cre/ 
IµBcl6; 
NikstopFL 
1110 
mLN DLBCL   
 
Spleen DLBCL   603 
mLN DLBCL   
604 Spleen DLBCL dim/hi ¶ hi/dim 
Spleen DLBCL hi dim 607 
mLN DLBCL   
Spleen DLBCL   775 
mLN DLBCL   
857 Spleen Plasmacytic lo/neg dim 
Spleen DLBCL hi dim 
Cγ1cre/ 
IµBcl6 
1128 
mLN DLBCL   
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Table S2. Surface Phenotype of Tumor Cells, Related to Figure 7 
 
 
Abbreviations: hi, high; lo, low; int, intermediate; N.D., not done. 
 
 
Cγ1-cre/IµBcl6 
Mice Surface phenotype 
603 CD19+, IgM+,   Igκ+, CD38hi, AA4.1-, CD21lo, CD23lo, CD138-, CD43- 
604 CD19+, IgM+,   Igκ+, CD38hi, AA4.1-, CD21lo, CD23lo, CD138-, CD43int  
607 CD19+, IgM+,   Igκ+, CD38hi, AA4.1-, CD21lo, CD23lo, CD138-, CD43int 
775 CD19+, IgG2+, Igκ+, CD38hi, AA4.1-, CD21lo, CD23lo, CD138-, CD43- 
857 N.D. 
1128 CD19+, IgM+,            CD38+, AA4.1-, CD21lo, CD23lo, CD138-, CD43- 
 
Cγ1-cre/IµBcl6;NikstopFL 
Mice Surface phenotype 
611 CD19+, IgM+,   Igκ+, CD38+, AA4.1-, CD21lo, CD23lo, CD138-, CD43- 
773 CD19+, IgM+,   Igκ+, CD38hi, AA4.1-, CD21lo, CD23lo, CD138-, CD43int 
776 CD19+, IgM+,   Igκ+, CD38hi, AA4.1-, CD21lo, CD23lo, CD138-, CD43- 
817 CD19+, IgM+,   Igκ+, CD38hi, AA4.1-, CD21lo, CD23lo, CD138-, CD43- 
818 CD19+, IgG3+, Igκ+, CD38hi, AA4.1-, CD21lo, CD23lo, CD138-, CD43- 
920 CD19+, IgM+,            CD38hi, AA4.1-, CD21lo, CD23lo, CD138-, CD43- 
1078 CD19+, IgM+,            CD38+, AA4.1-, CD21lo, CD23lo, CD138-, CD43+ 
1110 CD19+, IgM+,            CD38+, AA4.1-, CD21lo, CD23lo, CD138-, CD43- 
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Table S3. SHM Analysis of Tumor Samples, Related to Figure 7 
 
Genotype/Mice VH DH JH Nucleotides 
analyzed (#) 
Mutations 
(#) 
Frequency of 
mutation (%) 
Cγ1-cre/IµBcl6;NikstopFL       
#611 VH7183.a2.3 DST4 JH4 560 1 0.18 
#817 J558.33 DFL16.1 JH2 380 3 0.79 
#920 J558.45 DQ52 JH2 380 0 0 
#1078 J558.19.109 DFL16.1 JH1 320 0 0 
 
Cγ1-cre/IµBcl6       
#603 J558.35 DSP2.8 JH3 530 3 0.57 
#604 VH7183.a47.76 DSP2.12 JH3 480 5 1.04 
#607 J558.n DSP2.2 JH3 530 1 0.19 
#1128 VH105 DSP2.7 JH4 560 0 0 
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Flow Cytometry 
Single cell suspensions prepared from various lymphoid organs were stained with the 
following antibodies: anti-CD19 (1D3), -B220 (RA3-6B2), -CD138 (281-2), -Fas (Jo2), -
CD43 (S7), -Igκ (187.1), -IgG2a/2b (R2-40), -IgG3 (R40-82) (all from BD); anti-CD93 
(AA4.1), -CD38 (90) (eBioscience); anti-CD21 (7E9), -CD23 (B3B4) (Biolegend); anti-
IgM (Fab fragment, Jackson Immunoresearch). Samples were acquired on a 
FACSCanto II (BD), and analyzed using FlowJo software (Tree Star). 
 
Real-Time RT-PCR 
Total RNA was extracted using TRIzol reagent, and cDNA was synthesized using the 
ThermoScript RT-PCR System (Invitrogen). For qRT-PCR we used Power SYBR 
Green, followed by analysis with the StepOnePlus System (Applied Biosystems). 
Samples were assayed in triplicate, and values normalized to HPRT levels.  
Primer sequences: 
 
Cell Culture, Apoptosis and Proliferation Assays 
5′-GCCCACGTTCCCGGAGGAGA-3′ Bcl6 
5′-CGTCTGCAGCGTGTGCCTCT-3′ 
5′-AGGTCTGCTGAAGCCTTGGC-3′ Irf4 
5′-CTTCAGGGCTCGTCGTGGTC-3′ 
5′-GGCTCCACTACCCTTATCCTGGAGG-3′ Blimp1 
5′-ACGCTGTACTCTCTCTTGGGGACAC-3′ 
5′-TAGTGCCACCTCCTGCTCACT-3′ Aicda 
5′-CAACAATTCCACGTGGCAGCC-3′ 
5′-GTCATGCCGACCCGCAGTC-3′ Hprt 
5′-GTCCTGTCCATAATCAGTCCATGAGGAATAAAC-3′ 
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Splenic B cells were purified by CD43-depletion (Miltenyi). Cells were cultured in the 
presence of 1 µg/ml anti-CD40 (HM40-3; eBioscience) and 25 ng/ml IL-4 (R&D 
Systems). To monitor cellular division, B cells were labeled with CellTraceTM Violet 
(Invitrogen) per the manufacturer’s instructions. Cells undergoing apoptosis were 
detected using the Active Caspase-3 Apoptosis Kit (BD), according to manufacturer’s 
instructions. 
 
Histology and Immunohistochemistry 
For histological examination, tissues were fixed with 10% formalin (Sigma), embedded 
in paraffin, sectioned at 5 µm and stained with hematoxylin and eosin (H&E). 
Immunohistochemical staining was performed with anti-IRF4 (MUM1; Santa Cruz), anti-
BCL6 (D65C10; Cell Signaling Technology), anti-CD138 (281-2; BD), and anti-mouse Ig 
(Vector). 
 
Immunoblot Analysis 
Protein extracts were fractionated on 10% sodium dodecyl sulfate polyacrylamide gels, 
transferred onto polyvinylidene difluoride membranes, and immunoblotted with the 
following primary antibodies: anti-NF-κB2 p100 (#4882), anti-phospho-IκBα (#9246), 
anti-BCL6 (#5650) (all from Cell Signaling Technology); anti-IκBα (SC-371, Santa 
Cruz), and anti-β-Actin (A5316, Sigma). 
 
Serum Protein Electrophoresis 
Serum was diluted 1:2 in barbital buffer and analyzed on a Hydragel K20 system 
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according to manufacturer’s instruction (Sebia). 
 
Analysis of Tumor Clonality 
The clonality of lymphomas was determined by Southern blotting of EcoRI-digested 
genomic DNA from tumors using a JH probe spanning the JH4 exon and part of the 
downstream intronic sequence. 
 
IgH Somatic Mutation Analysis 
Genomic DNA was prepared from tumor tissues or sorted GC B cells. IgH-V gene 
rearrangements were PCR amplified using the Expand High Fidelity PCR System 
(Roche) with forward primers VHA and VHE adapted from (Ehlich et al., 1994) and a 
reverse primer in the JH4 intron (5’-CTCCACCAGACCTCTCTAGACAGC-3’). 
Fragments were cloned, sequenced, and blasted against the NCBI database 
(http://www.ncbi.nlm.nih.gov/igblast/) to determine VHDHJH usage. The cloned intronic 
sequences were then aligned to their germline counterparts. In determining somatic 
mutations we excluded polymorphisms associated with the Cγ1-cre allele. 
 
RNA Sequencing and Analysis 
Illumina TrueSeq mRNA-seq libraries were prepared from total RNA according to the 
manufacturer's instructions (Illumina). All libraries were sequenced in 6-plex pools, two 
lanes per pool, for 1x101 cycles on an Illumina HiSeq2000 instrument. An average of 
65,061,816 single-end 101bp reads were generated per sample, of which ~93.37% on 
average could be mapped onto the ENSEMBL NCBIM37.67 mouse reference genome 
 14 
sequence using TopHat (Trapnell et al., 2009). An average of 72.59% of all mapped 
bases per sample were aligned within ENSEMBL gene bodies. For expression analysis, 
reads uniquely mapping to individual ENSEMBL genes were counted using htseq-count 
(http://www-huber.embl.de/users/anders/HTSeq). Gene expression was quantified using 
edgeR based on a negative binomial generalized log-linear model (Robinson et al., 
2010). Biological reproducibility between the replicates was excellent (Pearson 
correlation: 0.990899). For classification of the mouse DLBCLs, hierarchical clustering 
was applied based on the expression of all genes. Euclidean distance and complete 
linkage was used to assess the similarity between individual DLBCL samples and GC B 
cells (GCB), resting B cells (Resting B), or in vitro activated B cells (ABC) prepared 
using anti-CD40 and anti-IgM antibodies. Sequence variants were detected within the 
mRNA-seq reads using VarScan (Koboldt et al., 2009). A minimum coverage of 10 
uniquely mapping reads in each sample was required in order to call a variant. Variants 
with alternative allele frequencies between 8% and 75% were defined as being 
heterozygous. Sequence variants were annotated with their predicted effect on protein 
coding sequence using snpEff (PMID: 22728672) based on ENSEMBL NCBIM37.67 
gene models. Somatic variants and loss-of-heterozygosity events were extracted from 
the total list of variants by comparing each tumor sample to the resting B-cell control 
samples. The VarScan probability of a variant to be somatic was thresholded at a 5% 
false-positive rate. 
 
 
List of NF-κB Related Genes Analyzed for Mutation in the Mouse Tumors 
BCL10, BIRC2 (cIAP1), BIRC3 (cIAP2), CARD11, CD40, CHUK (IKKα), CSNK1A1, 
CYLD, IKBKB (IKKβ), IKBKG (NEMO), Tnfrsf11a (Rank), MALT1, MAP3K14 (NIK), 
MAP3K7 (TAK1), MAP3K7IP2 (TAB2), MAP3K7IP3 (TAB3), NFKB1 (p105/p50), 
NFKBIA (IκBα), NFKBIB (IκBβ), PRKCB1, REL (cREL), TNFAIP3 (A20), TNFRSF11A 
(RANK), TNFRSF13C (BAFFR), TNFSF13B (BAFF), TRAF1, TRAF2, TRAF3, TRAF4, 
TRAF5, TRAF6, TBK1, MYD88, CD79b  15 
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